OR WAIT null SECS
© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Supply-chain visibility systems are proving their worth in the distribution of COVID-19 vaccines.
FDA’s response to COVID-19 may impact the biologics industry long term.
With vaccine development prioritized during the COVID-19 pandemic, innovations have to accelerated development processes.
Although vials and prefilled syringes have different advantages, both find use in vaccine fill/finish.
June 18, 2021
CureVac’s first-generation COVID-19 vaccine candidate, CvnCoV, did not meet efficacy targets in a second interim analysis.
The US government will invest $3 billion from the American Rescue Plan into a COVID-19 antiviral development strategy.
Recent analysis has shown that two doses of COVID-19 vaccines are highly effective against hospitalization as a result of infection with the Delta variant of COVID-19.
June 15, 2021
What can the biopharma industry learn from its rapid response to the COVID-19 pandemic?
Novavax’s COVID-19 vaccine is 90.4% effective and maintains efficacy when administered with an influenza vaccine.
June 14, 2021
The agency approved two batches of drug substance manufactured at the Emergent BioSolutions facility in Baltimore for use in the Janssen COVID-19 vaccine.
June 11, 2021
As a safety measure, supervisory authorities in the European Union have recommended not releasing batches of Janssen’s COVID-19 vaccine with API manufactured at Emergent BioSolutions’ Maryland facility.
The new site in Monts, France, which is operated by Recipharm, will produce finished COVID-19 vaccine product.
June 08, 2021
The vaccine is now authorized for ages 12 and older in European Union member states and the UK.
AGC Biologics has partnered with BioNTech to further supply plasmid DNA starting material from its Heidelberg, Germany, facility for the Pfizer-BioNTech COVID-19 vaccine.